Bristol-Myers Squibb Company (BMY) — Stock Price, Chart & Analysis
Bristol-Myers Squibb Company (BMY) is a Healthcare stock currently trading at $62.62, up 15.96% on the day. It carries a market capitalization of $127.16B and a trailing P/E ratio of 13.80. Over the past 52 weeks, BMY has traded between $42.52 and $68.64. Bristol-Myers Squibb Company pays a dividend yielding 4.0%. View the live BMY chart, technical opinion, analyst ratings, fundamentals and latest news below.
Bristol-Myers Squibb Company (BMY) key data
| Price | $62.62 |
| Change (today) | +15.96% |
| Previous close | $54 |
| Market cap | $127.16B |
| P/E ratio (TTM) | 13.80 |
| EPS (TTM) | $4.51 |
| Dividend yield | 4.0% |
| 52-week high | $68.64 |
| 52-week low | $42.52 |
| Beta | 0.23 |
| Avg. volume | 11.09M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Bristol-Myers Squibb Company (BMY)
How much does one share of Bristol-Myers Squibb Company cost?
As of the latest update, one share of Bristol-Myers Squibb Company (BMY) trades at $62.62 (+15.96% today).
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company has a market capitalization of approximately $127.16B.
What is Bristol-Myers Squibb Company's P/E ratio?
Bristol-Myers Squibb Company has a trailing price-to-earnings (P/E) ratio of 13.80.
What is Bristol-Myers Squibb Company's earnings per share (EPS)?
Bristol-Myers Squibb Company's trailing twelve-month EPS is $4.51.
Does Bristol-Myers Squibb Company pay a dividend?
Yes — Bristol-Myers Squibb Company pays a dividend with a yield of 4.0% ($2.52 per share annually).
What is Bristol-Myers Squibb Company's 52-week trading range?
Over the past year, BMY has traded between $42.52 and $68.64.
What is the analyst price target for Bristol-Myers Squibb Company?
The mean analyst price target for Bristol-Myers Squibb Company is $66.71. This is informational only and not investment advice.
Latest Bristol-Myers Squibb Company (BMY) news
- Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense networkNews · Sep 21, 2026
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderNews · Sep 20, 2026
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?News · Sep 18, 2026
- Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?News · Sep 18, 2026
- Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?News · Sep 18, 2026
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?News · Sep 18, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live BMY dashboard…